Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 7Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Endometrial Adenocarcinoma 1

Interventions

pembrolizumab 85Specimen Handling 79Carboplatin 73Magnetic Resonance Spectroscopy 71Biopsy 58Nivolumab 55Cisplatin 54Paclitaxel 46Cyclophosphamide 44durvalumab 37Radiotherapy 36Radiation 35olaparib 34Rituximab 34Etoposide 33Dexamethasone 33Ipilimumab 30Gemcitabine 30Lenalidomide 28Taxes 27Doxorubicin 27Docetaxel 27Pemetrexed 26Bevacizumab 24Prednisone 23Cytarabine 23X-Rays 22Trastuzumab 21cabozantinib 20Disulfides 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Has results × Epothilones × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡